[Red blood cell immunization in haemoglobinopathie: about 84 cases].

Area of Science:

• Hematology
• Immunology
• Transfusion Medicine

Context:

• Hemoglobinopathies, such as sickle cell disease and thalassemia, often require chronic blood transfusions.
• Transfusion-dependent patients are at high risk for developing red blood cell antibodies (alloimmunization).
• Previous transfusion strategies may not have adequately addressed the risk of alloimmunization.

Purpose:

• To estimate the rate of red cell alloimmunization in patients with hemoglobinopathies.
• To evaluate the effectiveness of RH-KELL phenotyped compatible red cell transfusions in reducing alloimmunization.
• To identify factors associated with alloimmunization and autoimmunization in this patient population.

Summary:

• A prospective study followed 84 patients with hemoglobinopathies from 1990-2009, transfusing ABORH1 compatible units, then RH-KELL phenotyped and phenocompatible units after 2006.
• Twenty-seven antibodies were identified, with 14 alloantibodies and 16 autoantibodies. Anti-RH3 and anti-KEL1 were the most frequent alloantibodies, developing after standard unit transfusions.
• While no significant relation was found between sex or unit number and alloimmunization, autoimmunization in thalassemia showed a significant relation to the number of units transfused.

Impact:

• The study demonstrates the benefit of using RH-KELL compatible red cell units to decrease alloimmunization rates in hemoglobinopathy patients.
• Implementing RH-KELL phenotyping and phenocompatible transfusions can improve transfusion safety and efficacy.
• Findings support updated transfusion guidelines for managing patients with hemoglobinopathies and preventing transfusion reactions.